 | Up a level |
Schirmer, J H; Aries, P M; Balzer, K; Berlit, P; Bley, T A; Buttgereit, F; Czihal, M; Dechant, C; Dejaco, C; Garske, U; Henes, J; Holle, J U; Holl-Ulrich, K; Lamprecht, P; Nölle, B; Moosig, F; Rech, J; Scheuermann, K; Schmalzing, M; Schmidt, W A; ... (2020). [S2k guidelines (executive summary): management of large-vessel vasculitis]. Zeitschrift für Rheumatologie, 79(9), pp. 937-942. Springer-Medizin-Verlag 10.1007/s00393-020-00894-0
Schirmer, J H; Aries, P M; Balzer, K; Berlit, P; Bley, T A; Buttgereit, F; Czihal, M; Dechant, C; Dejaco, C; Garske, U; Henes, J; Holle, J U; Holl-Ulrich, K; Lamprecht, P; Nölle, B; Moosig, F; Rech, J; Scheuermann, K; Schmalzing, M; Schmidt, W A; ... (2020). [S2k guidelines: management of large-vessel vasculitis]. Zeitschrift für Rheumatologie, 79(Suppl 3), pp. 67-95. Springer-Medizin-Verlag 10.1007/s00393-020-00893-1
Aringer, M; Burkhardt, H; Burmester, G R; Fischer-Betz, R; Fleck, M; Graninger, W; Hiepe, F; Jacobi, A M; Kötter, I; Lakomek, H J; Lorenz, H M; Manger, B; Schett, G; Schmidt, R E; Schneider, M; Schulze-Koops, H; Smolen, J S; Specker, C; Stoll, T; Strangfeld, A; ... (2012). Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus, 21(4), pp. 386-401. London: Sage 10.1177/0961203311426569
Delforge, M; Farber, C M; Spath, P; Kaveri, S; Witte, T; Misbah, S A; Hübner, R; Haerynck, F; Latinne, D; Muylle, L; Toungouz, M; Deneys, V; Superior Health Council Belgium, (2011). Recommended indications for the administration of polyclonal immunoglobulin preparations. Acta clinica belgica, 66(5), pp. 346-60. Brussels: Acta clinica belgica 10.2143/ACB.66.5.2062586
